Moving Forward With Expanding to an “All-RAS Mutational Analysis” in Metastatic Colorectal Cancer: Beyond KRAS Mutations

Restricted access

Tanios Bekaii-Saab, MD, is section chief for the gastrointestinal oncology program and an associate professor of medicine and pharmacology at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. His research focuses on translational therapeutics in gastrointestinal malignancies, and he is the principal investigator on numerous studies supported by grants from NIH/NCI, NCCN, and industry partners. Dr. Bekaii-Saab is a member of the NCCN Colorectal Cancer Panel and is on the editorial board for JNCCN. He has received leadership awards from NCI and ASCO, and has been named in the “Best Doctors in America” and “Top Castle Connolly Doctor” lists for the past few consecutive years.

Dr. Bekaii-Saab earned his medical degree at the American University of Beirut in Lebanon, completed his internal medicine residency at Indiana University Medical Center, and completed fellowships in oncology and clinical pharmacology at Tufts University-New England Medical Center in Boston. He joined Ohio State in 2002.

The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 53 43 1
PDF Downloads 11 10 1
EPUB Downloads 0 0 0